Glancy Prongay & Murray Commences Investigation on Behalf of CBL & Associates Properties, Inc. Investors
Get Alerts CBL Hot Sheet
Join SI Premium – FREE
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of CBL & Associates Properties, Inc. (“CBL” or the “Company”) (NYSE: CBL) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
On May 24, 2016, after the market close, the Wall Street Journal (“WSJ”) reported that the FBI and SEC are investigating whether CBL officials falsified info on financial statements to banks when applying for financial arrangements. According to the WSJ the Company allegedly inflated its rental income and occupancy rates when reporting these figures.
On this news, CBL shares fell $1.26 per share, or nearly 13%, during intraday trading on May 25, 2016.
If you purchased CBL securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160525006113/en/
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com
Source: Glancy Prongay & Murray LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Enterprises raises dividend 5%, adds board member
- Galectin reaches FDA agreement on belapectin Phase 3 trial design
- Gorilla Technology signs $2.5B AI compute contract in Indonesia
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share